Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs
Toxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-06-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcimb.2020.00289/full |
| _version_ | 1818969806895841280 |
|---|---|
| author | Sergio O. Angel Laura Vanagas Diego M. Ruiz Constanza Cristaldi Ana M. Saldarriaga Cartagena William J. Sullivan William J. Sullivan |
| author_facet | Sergio O. Angel Laura Vanagas Diego M. Ruiz Constanza Cristaldi Ana M. Saldarriaga Cartagena William J. Sullivan William J. Sullivan |
| author_sort | Sergio O. Angel |
| collection | DOAJ |
| description | Toxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii is a foodborne pathogen. In addition, chronic toxoplasmosis in goats and sheep is the cause of recurrent abortions with economic losses in the sector. It is also a health problem in pets such as cats and dogs. Although there are therapies against this infection in its acute stage, they are not able to permanently eliminate the parasite and sometimes they are not well tolerated. To develop better, safer drugs, we need to elucidate key aspects of the biology of T. gondii. In this review, we will discuss the importance of the homologous recombination repair (HRR) pathway in the parasite's lytic cycle and how components of these processes can be potential molecular targets for new drug development programs. In that sense, the effect of different DNA damage agents or HHR inhibitors on the growth and replication of T. gondii will be described. Multitarget drugs that were either associated with other targets or were part of general screenings are included in the list, providing a thorough revision of the drugs that can be tested in other scenarios. |
| first_indexed | 2024-12-20T14:26:27Z |
| format | Article |
| id | doaj.art-6c44625a108c4d98ac6bba54fb981f4c |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-12-20T14:26:27Z |
| publishDate | 2020-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-6c44625a108c4d98ac6bba54fb981f4c2022-12-21T19:37:47ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882020-06-011010.3389/fcimb.2020.00289536371Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic DrugsSergio O. Angel0Laura Vanagas1Diego M. Ruiz2Constanza Cristaldi3Ana M. Saldarriaga Cartagena4William J. Sullivan5William J. Sullivan6Laboratorio de Parasitología Molecular, Instituto Tecnológico Chascomús (INTECH), Consejo Nacional de Investigaciones Científicas (CONICET)-Universidad Nacional General San Martin (UNSAM), Chascomús, ArgentinaLaboratorio de Parasitología Molecular, Instituto Tecnológico Chascomús (INTECH), Consejo Nacional de Investigaciones Científicas (CONICET)-Universidad Nacional General San Martin (UNSAM), Chascomús, ArgentinaLaboratorio de Parasitología Molecular, Instituto Tecnológico Chascomús (INTECH), Consejo Nacional de Investigaciones Científicas (CONICET)-Universidad Nacional General San Martin (UNSAM), Chascomús, ArgentinaLaboratorio de Parasitología Molecular, Instituto Tecnológico Chascomús (INTECH), Consejo Nacional de Investigaciones Científicas (CONICET)-Universidad Nacional General San Martin (UNSAM), Chascomús, ArgentinaLaboratorio de Parasitología Molecular, Instituto Tecnológico Chascomús (INTECH), Consejo Nacional de Investigaciones Científicas (CONICET)-Universidad Nacional General San Martin (UNSAM), Chascomús, ArgentinaPharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, United StatesMicrobiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesToxoplasma gondii is the causative agent of toxoplasmosis in animals and humans. This infection is transmitted to humans through oocysts released in the feces of the felines into the environment or by ingestion of undercooked meat. This implies that toxoplasmosis is a zoonotic disease and T. gondii is a foodborne pathogen. In addition, chronic toxoplasmosis in goats and sheep is the cause of recurrent abortions with economic losses in the sector. It is also a health problem in pets such as cats and dogs. Although there are therapies against this infection in its acute stage, they are not able to permanently eliminate the parasite and sometimes they are not well tolerated. To develop better, safer drugs, we need to elucidate key aspects of the biology of T. gondii. In this review, we will discuss the importance of the homologous recombination repair (HRR) pathway in the parasite's lytic cycle and how components of these processes can be potential molecular targets for new drug development programs. In that sense, the effect of different DNA damage agents or HHR inhibitors on the growth and replication of T. gondii will be described. Multitarget drugs that were either associated with other targets or were part of general screenings are included in the list, providing a thorough revision of the drugs that can be tested in other scenarios.https://www.frontiersin.org/article/10.3389/fcimb.2020.00289/fullToxoplasma gondiiDNA repairDNA damagedrugtherapy |
| spellingShingle | Sergio O. Angel Laura Vanagas Diego M. Ruiz Constanza Cristaldi Ana M. Saldarriaga Cartagena William J. Sullivan William J. Sullivan Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs Frontiers in Cellular and Infection Microbiology Toxoplasma gondii DNA repair DNA damage drug therapy |
| title | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs |
| title_full | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs |
| title_fullStr | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs |
| title_full_unstemmed | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs |
| title_short | Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs |
| title_sort | emerging therapeutic targets against toxoplasma gondii update on dna repair response inhibitors and genotoxic drugs |
| topic | Toxoplasma gondii DNA repair DNA damage drug therapy |
| url | https://www.frontiersin.org/article/10.3389/fcimb.2020.00289/full |
| work_keys_str_mv | AT sergiooangel emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT lauravanagas emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT diegomruiz emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT constanzacristaldi emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT anamsaldarriagacartagena emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT williamjsullivan emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs AT williamjsullivan emergingtherapeutictargetsagainsttoxoplasmagondiiupdateondnarepairresponseinhibitorsandgenotoxicdrugs |